The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 33, 2007, Pages 13283-13288

  Hantschel, Oliver ^a   Rix, Uwe ^a   Schmidt, Uwe ^b,d   Bürckstümmer, Tilmann ^a   Kneidinger, Michael ^c   Schütze, Gregor ^a   Colinge, Jacques ^a   Bennett, Keiryn L ^a   Ellmeier, Wilfried ^b   Valent, Peter ^c   Superti Furga, Giulio ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Nabriva Therapeutics Inc   (Austria)

Author keywords

Kinase inhibitor; Leukemia; Tec kinases

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CYTOKINE; DASATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE BTK; PROTEIN TYROSINE KINASE TEC; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BASOPHIL; CELL LYSATE; CELL STRAIN K 562; CELL STRAIN U937; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BASOPHILS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTAMINE RELEASE; HUMANS; K562 CELLS; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; U937 CELLS;

MUS; PYRONIA TITHONUS;

EID: 34548097263     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0702654104     Document Type: Article

References (37)

1. Wong S, Witte ON (2004) Annu Rev Immunol 22:247-306.
2. Deininger M, Buchdunger E, Druker BJ (2005) Blood 105:2640-2653.
3. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Science 289:1938-1942.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. (2006) N Engl J Med 355:2408-2417.
5. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Cancer Res 56:100-104.
6. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Cancer Res 62:4236-4243.
7. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J (2003) Cell 112:859-871.
8. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP (2004) J Biol Chem 279:31655-31663.
9. Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J, Sawyers C (2002) Cancer Cell 2:117-125.
10. O'Hare T, Corbin AS, Druker BJ (2006) Curr Opin Genet Dev 16:92-99.
11. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. (2004) J Med Chem 47:6658-6661.
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Science 305:399-401.
13. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P (2006) Nat Rev Drug Discov 5:717-718.
14. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005) Cancer Res 65:4500-4505.
15. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, III, Edeen PT, et al. (2005) Proc Natl Acad Sci USA 102:11011-11016.
16. Burdine L, Kodadek T (2004) Chem Biol 11:593-597.
17. Guiffant D, Tribouillard D, Gug F, Galons H, Meijer L, Blondel M, Bach S (2007) Biotechnol J 2:68-75.
18. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Muller S, Daub H (2004) Mol Cell Proteom 3:1181-1193.
19. Fabian MA, Biggs WH, III, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al. (2005) Nat Biotechnol 23:329-336.
20. Daub H (2005) Biochim Biophys Acta 1754:183-190.
21. Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M (2001) BioEssays 23:436-446.
22. Hantschel O, Superti-Furga G (2004) Nat Rev Mol Cell Biol 5:33-44.
23. Lewis CM, Broussard C, Czar MJ, Schwartzberg PL (2001) Curr Opin Immunol 13:317-325.
24. Vihinen M, Mattsson PT, Smith CI (2000) Front Biosci 5:D917-D928.
25. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, et al. (2006) Cancer Res 66:5790-5797.
26. Mao C, Zhou M, Uckun FM (2001) J Biol Chem 276:41435-41443.
27. Brown K, Long JM, Vial SC, Dedi N, Dunster NJ, Renwick SB, Tanner AJ, Frantz JD, Fleming MA, Cheetham GM (2004) J Biol Chem 279:18727-18732.
28. Horwood NJ, Mahon T, McDaid JP, Campbell J, Mano H, Brennan FM, Webster D, Foxwell BM (2003) J Exp Med 197:1603-1611.
29. Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C, Scharenberg AM, Kinet JP, Witte ON (1996) Immunity 4:515-525.
30. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al. (2005) Cancer Cell 7:129-141.
31. Hata D, Kawakami Y, Inagaki N, Lantz CS, Kitamura T, Khan WN, Maeda-Yamamoto M, Miura T, Han W, Hartman SE, et al. (1998) J Exp Med 187:1235-1247.
32. Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, Maeda-Yamamoto M, Lowell CA, Rawlings DJ, Witte ON, Kawakami T (2000) J Immunol 165:1210-1219.
33. Martinelli G, Soverini S, Rosti G, Baccarani M (2005) Leukemia 19:1872-1879.
34. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. (2006) N Engl J Med 354:2531-2541.
35. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, et al. (2007) Blood 109:5143-5150.
36. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, et al. (2005) J Exp Med 201:1837-1852.
37. Zhou S, Carraway KL, III, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, et al. (1995) Nature 373:536-539.